A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2019
INTERVENTION: Experimental group:Traditional Chinese medicine (Yi‐Shen Tong‐Bi Tang);Positive control group:Methotrexate; CONDITION: Rheumatoid Arthritis PRIMARY OUTCOME: CDAI;SDAI; SECONDARY OUTCOME: DAS28;ACR20;ACR50;ACR70; INCLUSION CRITERIA: 1. Meet the 2010 European League Against Rheumatism and the American College of Rheumatology RA classification criteria and have a RA course of at least 6 weeks; 2. Aged 18‐65 years old; 3. AT least three swollen joints (SJC) and five tender joints (TJC); 4. Erythrocyte sedimentation rate (ESR)>28mm/h or C‐reactive protein (CRP)>20mg/L; 5. Sign the informed consent form.
Epistemonikos ID: efaec52341ab8f4d08c114a6c4eeaa2b572cb195
First added on: Mar 23, 2022